Exploring the association between melanoma and glioma risks

Annals of Epidemiology

Volumn 24, Issue 6, 2014, Pages 469-474

  Scarbrough, Peter M ^a   Akushevich, Igor ^a   Wrensch, Margaret ^b   Il'yasova, Dora ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Epidemiology; Glioblastoma; Glioma; Melanoma; SEER

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RADIATION INDUCED NEOPLASM; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STANDARDIZED INCIDENCE RATIO; CANCER REGISTRY; INCIDENCE; MIDDLE AGED; RISK FACTOR; SEX RATIO; SKIN NEOPLASMS; UNITED STATES;

ADULT; AGED; COHORT STUDIES; FEMALE; GLIOMA; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; RISK FACTORS; SEER PROGRAM; SEX DISTRIBUTION; SKIN NEOPLASMS; UNITED STATES;

EID: 84900790584     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.02.010     Document Type: Article

References (38)

1. Central Brain Tumor Registry of The United States Central Brain Tumor Registry of the United States, Available at:, [Accessed May 28, 2013]. http://www.CBTRUS.org.
2. Kleihues P., Cavenee W.K. Tumors of the central nervous system: pathology and genetics 1995, International Agency for Research on Cancer, Lyon, France.
3. Schwartzbaum J.A., Fisher J.L., Aldape K.D., Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006, 2:494-503.
4. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., et al. SEER cancer statistics review, 1975-2002 2005, National Cancer Institute, Bethesda, Md.
5. Surawicz T.S., McCarthy B.J., Kupelian V., Jukich P.J., Bruner J.M., Davis F.G. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999, 1:14-25.
6. Deorah S., Lynch C.F., Sibenaller Z.A., Ryken T.C. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 2006, 20:E1.
7. Bondy M.L., Scheurer M.E., Malmer B., Barnholtz-Sloan J.S., Davis F.G., Il'yasova D., et al. Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113:1953-1968.
8. Ron E. Cancer risks from medical radiation. Health Phys 2003, 85:47-59.
9. Thompson D.E., Mabuchi K., Ron E., Soda M., Tokunaga M., Ochikubo S., et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiat Res 1994, 137:S17-S67.
10. Linos E., Raine T., Alonso A., Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007, 99:1544-1550.
11. Kaufman D.K., Kimmel D.W., Parisi J.E., Michels V.V. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 1993, 43:1728-1731.
12. Azizi E., Friedman J., Pavlotsky F., Iscovich J., Bornstein A., Shafir R., et al. Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome. Cancer 1995, 76:1571-1578.
13. Paunu N., Pukkala E., Laippala P., Sankila R., Isola J., Miettinen H., et al. Cancer incidence in families with multiple glioma patients. Int J Cancer 2002, 97:819-822.
14. Bahuau M., Vidaud D., Jenkins R.B., Bièche I., Kimmel D.W., Assouline B., et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998, 58:2298-2303.
15. Scheurer M.E., Etzel C.J., Liu M., El-Zein R., Airewele G.E., Malmer B., et al. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 2007, 16:2491-2495.
16. Scheurer M.E., Etzel C.J., Liu M., Barnholtz-Sloan J., Wiklund F., Tavelin B., et al. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol 2010, 172:1099-1107. GLIOGENE Consortium.
17. McCarthy B.J., Rankin K., Il'yasova D., Erdal S., Vick N., Ali-Osman F., et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev 2011, 20:370-378.
18. Hankey B.F., Ries L.A., Edwards B.K. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999, 8:1117-1121.
19. SEER*Stat database: SEER 17 registries research data and Hurricane Katrina impacted Louisiana cases Surveillance, Epidemiology, and End Results (SEER) Program, Available at:, [Accessed May 28, 2013]. http://www.seer.cancer.gov.
20. Supplement report: primary brain tumors in the United States, 2004 2008, Central Brain Tumor Registry of the United States, Published by the Central Brain Tumor Registry of the United States, Hinsdale, IL.
21. Dubrow R., Darefsky A.S. Demographic variation in incidence of adult glioma by subtype, United States, 2002-2007. BMC Cancer 2011, 11:325.
22. Breslow N.E., Day N.E. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ 1987, 1-406.
23. Watson M., Johnson C.J., Chen V.W., Thomas C.C., Weir H.K., Sherman R., et al. Melanoma surveillance in the United States: overview of methods. J Am Acad Dermatol 2011, 65:S6-S16.
24. Akushevich I., Kravchenko J., Ukraintseva S., Arbeev K., Yashin A.I. Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. Age Ageing 2013, 42:494-500.
25. Purdue M.P., Freeman L.E., Anderson W.F., Tucker M.A. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008, 128:2905-2908.
26. Strodtbeck K., Sloan A., Rogers L., Fisher P.G., Stearns D., Campbell L., et al. Risk of subsequent cancer following a primary CNS tumor. J Neurooncol 2013, 112:285-295.
27. Inskip P.D. Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer. Cancer 2003, 98:562-570.
28. Spanogle J.P., Clarke C.A., Aroner S., Swetter S.M. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010, 62:757-767.
29. Salminen E., Pukkala E., Teppo L. Second cancers in patients with brain tumours-impact of treatment. Eur J Cancer 1999, 35:102-105.
30. Inskip P.D., Tarone R.E., Hatch E.E., Wilcosky T.C., Fine H.A., Black P.M., et al. Sociodemographic indicators and risk of brain tumours. Int J Epidemiol 2003, 32:225-233.
31. McCarthy B.J., Propp J.M., Davis F.G., Burger P.C. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 2008, 30:34-44.
32. Kayserova J., Sismova K., Zentsova-Jaresova I., Katina S., Vernerova E., Polouckova A., et al. A prospective study in children with a severe form of atopic dermatitis: clinical outcome in relation to cytokine gene polymorphisms. J Investig Allergol Clin Immunol 2012, 22:92-101.
33. Solomon D.A., Kim J.S., Cronin J.C., Sibenaller Z., Ryken T., Rosenberg S.A., et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 2008, 68:10300-10306.
34. Kuan C.T., Wakiya K., Keir S.T., Li J., Herndon J.E., Pastan I., et al. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer 2011, 129:111-121.
35. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013, 110:6021-6026.
36. Scharti M., Wilde B., Laisney J.A., Taniguchi Y., Takeda S., Meierjohann S. A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies. J Invest Dermatol 2010, 130:249-258.
37. Rhim K.J., Hong S.I., Hong W.S., Lee S.Y., Lee D.S., Jang J.J. Aberrant expression of p53 gene product in malignant melanoma. J Korean Med Sci 1994, 9:376-381.
38. Qi Z.Y., Shao C., Zhang X., Hui G.Z., Wang Z. Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. PLoS One 2013, 16:e68695.